Vaishali Pharma Limited has informed the Exchange about Investor Presentation
November 28, 2023
To, The Manager National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai – 400 051
Stock Code: VAISHALI ISIN: INE972X01014
SUB: Announcement under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, we have enclosed herewith the Investor Presentation released by the Company. Further, pursuant to Regulation 46 of SEBI (Listing Obligations and Disclosure Requirements), 2015, the aforesaid information will also be available on the website of the Company i.e. https://www.vaishalipharma.com
The above information and attachment are for your record and reference.
Thanking you.
Yours faithfully, For Vaishali Pharma Limited,
__________________________________ Authorized Signatory
Place: Mumbai
Vaishali Pharma Limited Q2 FY24 Investor Presentation
Safe Harbour Statement
This presentation and the accompanying slides (the “Presentation”), which have been prepared by Vaishali Pharma Limited (‘Vaishali Pharma’, The Company) solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.
This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.
Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantee of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict.
These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks.
The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.
Investor Presentation
2
Company Overview
A Glimpse Into Vaishali Pharma
Incorporated in 1989, Vaishali Pharma Limited (‘Vaishali Pharma’, The Company), Mumbai based company has firmly established itself in the pharmaceutical sector, specializing in the production and marketing of Active Pharmaceutical Ingredients (APIs), Formulation, surgical products, veterinary supplements, herbal, nutraceutical, and oncology products. This vast portfolio caters to multiple therapeutic areas, addressing both human and animal health needs.
Initially venturing into the domain of API trading and marketing, the company expanded its horizons in 2012 to include the marketing of pharmaceutical formulations for a global clientele. The Company’s brands have now secured their position in numerous international markets, reflecting the company's global vision and commitment.
Vaishali Pharma, with its warehouse in Bhiwandi, Maharashtra, has a solid domestic footprint. Expanding globally, they've partnered with companies in D.R. Congo, Kenya, and Russia. The Company has established a strategic partnership with Sankalp Life Care, a prominent nutraceuticals manufacturer, enabling to oversee and operate Sankalp LifeCare's domestic and international marketing operations.
In a commendable stride of just two years, Vaishali secured its place as one of the leading player in Russia's veterinary product domain, positioning itself strongly in a globally renowned pharmaceutical market.
Investor Presentation
4
Essential Insights
40+ Countries
1,500+ Products
35+ Years of Experience
1,000+ Customers
250+ Brands
35+ Locations
Over 100 Tonnes Warehouse Capacity
WHO-GMP, EU-GMP & USFDA Approved Manufacturing Facilities
Investor Presentation
FY23 Revenue - ₹ 69.66 Cr EBITDA - ₹ 11.36 Cr PAT - ₹ 6.60 Cr
5
Guiding Principles: Mission, Vision, & Values
VISION
"To be a well recognised Indian MNC in the pharmaceuticals and healthcare industry”
"To contribute substantially towards well-being and health of the society by providing high quality products and service”
MISSION
VALUES
Investor Presentation
Total quality management Providing excellent customer support Building trust for long lasting business relationship To impact respect to all for individuals
6
The Evolution: Timeline Of Vaishali Pharma
1989
1994
2000
2008
2009
2011
2012
Inception as Vaishali Pharmachem, an Active Pharmaceutical Ingredients (API) Trading Company.
Joint venture with Arochem Industries, an API Manufacturing Company.
Expanded presence with a new office in Gujarat- Vapi.
Rebranded to Vaishali Pharma Pvt Ltd. Achieved ISO 9001:2008 certification for quality.
Remarkable 80% growth in Sales Turnover.
Expanded overseas with an office in Ho Chi Minh City, Vietnam.
Ventured into Formulation Manufacturing and Export. Achieved 120Cr Sales Turnover.
2022
2021
2020
2019
2017
2016
2013
Took over domestic and international marketing operations of Sankalp Life Care.
Exports expanded to 30+ countries.
Vaishali Pharma got listed on main board of NSE.
Introduced vertical of Nutraceutical Division.
Earned export house certification. Transformed from Private to Public.
Exports reached 20+ countries.
Introduced vertical of surgical division.
Investor Presentation
7
A Testament To Standards
Company Certifications
Surgical Certifications
ISO 9001 : 2015
ISO 13484 : 2016
Conformitè Europëenne
Investor Presentation
8
A Testament To Standards: Global Certifications
Formulation Certifications
_____________________________________ 1. ____________________________________ 1. ____________________________________ L ___________________________________ _
">' ollo.JG" M INISTRY OF H EALTH
MOHYEMEN
•
'''-+''*'I I..'. ;' ''~ l.. ... h;.4\~ t"J'oftl\.h rm."; 'tn, -t'ti'l't'C redenl.1 DemocnItic Republk: d Ethiopia Ministry ot 1·leallh
r: rt ~ A i ~! ~, fj~~ . /~ 2~'~~~\ ,v. ~ r'.
\\t-.1I.Ai\1 U " I,
MINISTRY OF HEAL Tr
~
~IlNISTRY OF HEALTH OFTHE REPUBLIC OF KAZAKHSTAN
- - - -
- - - - -
- - - - -
- - - - - - - - - -
- - - - - - - - -
- - - - - - - - -
- - - - - - - - - - T - - - -
- - - - -
- - - - - - - - - - - - _1. - - - - - - - - - - - - - - - - - - - - - - - - - - - - -1- - - -
- - - - - - - - - - - - - - - - - - -
- - - - - - - - -
-
- - - - - - - - - - - - - -
- - - - - , - - - - - - - - - - - - - - - - - - - - - - - - - - - -
------------------------- - -- - - -- -- -- -- - -- -- -- - - - - --- - -- -- - -- - - - -- -- - -- -- ----
~~ i (~~~\ , . . ....
' •
III
•
I~ ~~~~
'''''/(1),,, OR';/' Safe Drugs Save Lives
~I'i}j-,
toCoU,.0t I t11t0i Mlmot/:", d.< In Same
c Ministry of Health
t - of Om n
Sull
Investor Presentation
9
Servicing Clients Across The Globe
U.K
Morocco
Kazakhstan
Armenia
Kyrgyzstan
Uzbekistan
Turkmenistan Iran Iraq
Afghanistan
UAE
Tajikistan
Turkey
Jordan
Egypt
Russia
Myanmar
Guatemala
Nicaragua
Costa Rica
colombia
Peru
Brazil
Sudan
Nigeria
Cameroon
Uganda
Ghana
D.R Congo
Angola
Oman
Yemen
Thailand
Vietnam
Philippines
Ethiopia
Kenya
Tanzania
Sri Lanka
Cambodia
Papua New Guinea
Zimbabwe
Madagascar
Fiji
Lesotho
Investor Presentation
10
Company Office – Mumbai, India
Core Competencies
Global Presence
Strong Relations
Strong Product Portfolio
Vaishali Pharma boasts an expansive operation that stretches across multiple countries and regions. This extensive international footprint is a testament to the company’s recognition and its successful network of partners and distributors worldwide. the company's international footprint is not only expanding but also strengthening its global brand reputation.
The Company has consistently maintained strong, enduring relations with suppliers and distributors. Anchoring their success on these trust-based associations, the company has always emphasized a spirit of collaboration. This ethos of mutual respect and partnership has been a cornerstone, fueling both the company's growth and the success of its associates.
Vaishali Pharma offers a varied and premium selection of products, reflecting its dedication to healthcare excellence. With ongoing innovation, the company ensures its offerings cater to a wide array of health requirements, positioning itself as a leading name in the industry.
Asset Based Business Model
Strong Entry Barriers
Experienced Management
Vaishali Pharma operates with a solid foundation of tangible assets, ensuring reduced dependency on external variables. This model not only provides stability but also allows for greater scalability and adaptability in operations.
Vaishali Pharma's well-recognized brand and the trust it has garnered from its customer base strengthen its stance in the market. The industry's requisite registrations and certifications create inherent entry barriers, further consolidating the company's competitive position.
One of the company's strengths lies in its robust and seasoned management team. Their combined experience and expertise not only steer the company with strategic vision but also instill confidence in ensuring steady growth and adaptability in the ever-evolving market landscape.
Investor Presentation
11
Management Team Overview
Key Managerial Personnel
Mr. Atul Vasani Chairman & Managing Director
Mr. Dewansh Vasani Executive Director
• With over 30 years of experience in pharmaceutical sector, he
• He is responsible for purchase management
boasts an impressive track record and a dynamic business sense.
• His deep understanding of business economics positions them
expertly to forge strategic joint ventures and alliances.
• He excels in coordinating with various departments and
ensuring compliance, which play a pivotal role in streamlining the company's logistics operations.
Mr. Hemant Pathak Chief Executive Officer
Mr. Ratnesh Singh Chief Financial Officer
• With over 40 years in the pharmaceutical sector and experience
spanning across 90 countries worldwide
• He oversees export operations, strategic planning, and the
comprehensive management of the company.
• With a strong foundation built over 12 years in finance and
accounts management
• He manages company finances, ensures compliance with tax
norms like GST and Income Tax, and offers key financial insights through MIS updates to the management.
Investor Presentation
13
Key Managerial Personnel
Ms. Priyanka Vasani Chief Operating Officer
Dr. Prafulla Nandi Chief technical officer
• With a decade of invaluable experience in managing operations and
international business
• She ensures all operations and activities align with our strategy and goals, with a sharp ability to swiftly identify and anticipate issues.
• He has 30+ years' experience in Pharmaceutical Research & Global
Regulatory Affairs. He holds a Master's from BITS, Pilani, and a Pharmacy Doctorate from Utkal University.
• He's worked with Multiple MNCs like Apotex, Fresenius Kabi, and
Indian firms like Dr. Reddys, Sun, Wockhardt, Jubilant, and Laurus.
Mr. Rumit Gopani Vice President
Mrs. Madhuri Mehta Executive Assistant to CMD
• He has over a decade of experience in managing international
client, vendor, and business partner relationships.
• He specialize in market research, relationship-building, regulatory
compliance, trade show promotion, and cross-departmental coordination for export activities.
• She is associated with Vaishali Pharma for the past 11 years. • She manages nationwide procurement of finished pharmaceutical
formulations from all regions across India.
Investor Presentation
14
Business Overview
Business Framework: Domestic & Exports
Contract Manufacturing & Trading of APIs Supply of APIs for Export Captive Consumption
Domestic
Export
o Manufacturing & Export
• Pharmaceutical Formulations • Surgical Products • Veterinary Products • Herbal & Nutraceuticals
Products o Exports of APIs
Investor Presentation
16
A Spectrum Of Offerings: Product Portfolio
API Products
Formulation Products
Surgical Products
Veterinary Products
Nutraceutical Products
Oncology Products
Investor Presentation
17
Exploring Product Portfolio
API and Formulation Products
API is the primary component that gives a drug its therapeutic effect. On the other hand, a finished formulation or a formulation intermediate involves a combination of chemicals, including the active ingredients, mixed in precise proportions to create a specific medication. Vaishali Pharma take pride in providing an extensive range of APIs, crucial for the efficacy of various medicines.
Anti-Protozoal agent
Anti-Helminthic
Anti-Allergic
Anti-Inflammatory/ Analgesic/ Antipyretic
Anti Malerial
Anti-Osteoarthritis
Hepatic Disorder
Anti-Asthmatic
Vitamins
Anti-Fungal
Anti-Diarrheal/ Anti Protozoal/ Anti Parasitic
Anti-Hypertensive
Antibiotic
Anti-Diabetic
Excipients
Other Products
For over five years, Company has specialized in delivering high-quality, expertly designed surgical products that ensure optimal performance. Vaishali Pharma cater to all hospital and medical needs, equipping medical professionals with top-tier tools that enable to execute tasks with utmost precision and ease.
Surgical Products
infusion sets
Syringes
Gloves
Catheter
Cotton
Mask
Canulla
Miscellaneous
Investor Presentation
18
Exploring Product Portfolio
Veterinary products play an important role in preventing and managing animal diseases. Vaishali Pharma is dedicated to marketing these products, ensuring high- quality veterinary medications are accessible to all at reasonable prices.
Veterinary Products
Bolus
Injection
Powder
Solution
Oncology focuses on cancer prevention, diagnosis, and treatment. Vaishali Pharma boasts a specialized division devoted to anticancer products.
Oncology Products
Injection
Tablets
Capsules
Nutraceutical Products
Nutraceuticals are holistic therapies designed to enhance well-being, manage symptoms, and ward off harmful processes. Vaishali Pharma offers an extensive selection of these products, ensuring essential vitamins and minerals are replenished in the body.
Tablets
Effervescent Tablets
Chewable Tablets
Capsules
Powder
Sachet
Liquids
Gummies
Investor Presentation
19
Introducing New Products
Sedatives and Hypnotics
Vitamin C and Antifungals
Nutraceutical Sprays
Dexmedetomidine 100 mcg/ml
Vitamin C Effervescent Tablets
Folic Acid + Vitamin B12 spray
Propofol 1%
Chewable Ascorbic Acid Tablets with Zinc Orange Flavour
Vitamin D3 Spray
Chewable Ascorbic Acid Tablets BP Orange Flavour
Multi-Vitamin Spray
Itraconazole Capsules
Folic Acid
Luliconazole cream 1% w/w
Investor Presentation
20
Product Wise Revenue Breakup
In %
FY23
10
15
20
55
In %
FY22
10
50
15
25
Formulation
API
Surgical
Veterinary
Nutraceutical
Investor Presentation
21
Industry Overview
Global Market Dynamics
Surpassing the trillion-dollar mark, the global pharmaceutical landscape is evolving rapidly, with emerging markets and driving towards a healthier future by 2028
In 2023, the global pharmaceutical market is anticipated to surpass the US$ 1 trillion benchmark, marking a significant milestone for an industry dedicated to the research, development, production, and distribution of medications. Over the past two decades, this sector has witnessed robust growth, registering revenues of 1.48 trillion U.S. dollars in 2022 alone.
Source : statista.com Investor Presentation
Geographically, the United States stands out as the premier pharmaceutical market, but the dynamics are shifting with the rapid rise of emerging markets. These markets, often characterized by middle and low-income countries, encompass nations such as Brazil, India, Russia, Colombia, and Egypt, among others. Their combined potential is fast becoming a pivotal component of the global pharma landscape.
Diving deeper into the segments, Oncology Drugs emerge as the dominant category, with a projected market size of US$188.20 billion in 2023. This segment's prominence underscores the global urgency and investment in tackling cancer.
Looking forward, the horizon for the pharmaceutical industry seems promising. With a projected compound annual growth rate (CAGR) of 5.80% from 2023 to 2028, the market is poised to reach an estimated value of US$1,478.00 billion by the end of 2028. This growth trajectory underscores the vital role pharmaceuticals play in global health and wellbeing.
23
Government Initiatives And Schemes
India's Pharma Sector Boom: Targeting US$ 130 Billion by 2030 with CAGR of over 10%
➢ India's pharmaceutical industry projected to reach US$ 65 billion by 2024 and around US$ 130 billion by 2030. Currently, the industry is valued at approximately US$ 50 billion, with over US$ 25 billion from exports.
➢ India fulfills 20% of global generic drug exports and ranks among the top 12 global biotech destinations and is the 3rd largest in Asia Pacific. In 2022, the biotech industry was valued at US$ 80.12 billion.
➢ Indian pharma is set to represent 13% of the global market, focusing on quality, affordability,
and innovation.
➢ India produces 8% of the world’s APIs and contributes 57% of APIs to the WHO's prequalified
list.
➢ Medical devices sector in India currently stands at US$ 11 billion with a 1.5% share in the global Indian pharma companies have a significant presence in the US and EU
market. Also, prescription markets, boasting the highest number of FDA-approved plants outside the US.
➢ India's biotechnology industry is diverse and was valued at US$ 70.2 billion in 2020, projected
to reach US$ 150 billion by 2025.
➢ Medical devices market expected to grow at a 37% CAGR, reaching US$ 50 billion by 2025.
➢ CARE Ratings forecast an annual growth rate of ~11% for India's pharma business over the next
two years.
➢ India is the world's primary generic drugs supplier, covering 20% of the global volume and 60%
of the global vaccine demand.
➢ In August 2021, the Indian pharma market witnessed a 17.7% yearly growth, and its revenue is
projected to grow over 12% Y-o-Y in FY22.
Source : India Brand Equity Foundation IBEF)
Investor Presentation
Indian Pharmaceutical Market
In US$ Billion
130
65
42
2021
2024
2030P
24
Government Initiatives And Schemes
India accelerates healthcare innovation, emphasizing digital health records, pharmaceutical industry growth, and expanded access to affordable medicines.
In US$ Billion
As per the Union Budget 2023-24 A mission is set to eliminate sickle cell anemia by 2047 with screenings in tribal areas. New R&D initiatives in pharmaceuticals, establishment of 157 nursing colleges, and the recent approval of the National Medical Devices Policy, 2023, emphasize India's focus on healthcare advancement and innovation.
Ayushman Bharat Digital Mission (ABDM)- ABDM enables citizens to link health records to their ABHA numbers, streamlining healthcare decisions. Following successful trials in six Union Territories, over 173 million health accounts have been created by February 2022, incorporating 10,114 doctors and 17,319 health facilities
In March 2022, the Strengthening of Pharmaceutical Industry (SPI) Scheme was introduced with a financial commitment of Rs. 500 crore (US$ 665.5 million) for FY22 to FY26. Additionally, the Scheme for Development of Pharma Industry, an umbrella initiative, covers assistance for Bulk Drug and Medical Device Industries, Pharmaceutical Industry support (CDP-PS), Promotion and Development (PPDS), and Technology Upgradation (PTUAS).
Pradhan Mantri Bhartiya Jan Aushadhi Kendras (PMBJKs): The Government has set a target to increase the number of PMBJKs to 10,500 by the end of March 2025. Product basket of PMBJP comprises of 1,451 drugs and 240 surgical instruments.
Government Expenditure on Health in India
66.7
62.8
46
41.4
38.6
34.9
31.1
FY17
FY18
FY19
FY20
FY21
FY22
FY23
Source : India Brand Equity Foundation (IBEF), ICRA Report on Indian Pharmaceutical Sector, Union Budget 2023-24
Investor Presentation
25
Indian Pharma: FDI Boost, Global Reach, And PLI Strategy
Bolstering India's Pharmaceutical Industry Growth and Self-reliance
-
Increase in Investment is permitted for Greenfield 100% FDI pharmaceutical projects, while Brownfield projects allow up to 74% FDI automatically and more with government approval. From April 2000 to December 2022, the Drugs and Pharmaceuticals industry saw a cumulative FDI inflow of US$ 21.22 billion, representing 3% of total FDI across all sectors. Indian pharma firms dominate the prescription markets in the US and EU, boasting the highest number of FDA- approved facilities outside the US.
Production Linked Incentive (PLI) - In June 2021, Finance Minister Ms. Nirmala Sitharaman designated an extra outlay of Rs. 197,000 crore (US$ 26,578.3 million) for a five-year pharmaceutical PLI scheme covering 13 sectors, including active pharmaceutical ingredients. To bolster self- reliance and reduce import the Department of Pharmaceuticals introduced a PLI scheme, encouraging domestic production in greenfield plants. This scheme, spanning FY21 to FY30, has an allocation of Rs. 6,940 crore (US$ 951.27 million) targeting four specific segments.
reliance on crucial bulk drugs,
Drugs & Pharmaceuticals Exports from India
19.14
20.70
22.44
24.60
25.39
In US$ Billion
16.89
16.78
17.28
FY16
FY17
FY18
FY19
FY20
FY21
FY22
FY23
Source : India Brand Equity Foundation, BMI, Business Standard
Investor Presentation
26
Financial Overview
Q2 FY24 Performance Highlights
Total Income
13.89
12.86
EBITDA & PAT
EBITDA
PAT
2.95
3.32
1.99
EBITDA Margin & PAT Margin
EBITDA%
PAT%
23.90
22.97
1.70
14.33
13.24
Q2 FY23
Q2 FY24
Q2 FY23
Q2 FY24
Q2 FY23
Q2 FY24
Investor Presentation
28
Amount In ₹ Cr & Margin in %
Last Four Quarter Performance
Particular
Revenue
Other Income
Total Income
Total Expenditure
EBITDA
Interest
Depreciation
PBT
Tax
PAT
Profit After Comprehensive Income
Q2 FY24
Q1 FY24
Q4 FY23
Q3 FY23
Q2 FY23
In ₹ Cr
12.57
0.30
12.86
9.91
2.95
0.47
0.12
2.36
0.66
1.70
1.70
13.42
0.36
13.78
11.11
2.67
0.43
0.12
2.12
0.53
1.59
1.59
26.24
0.53
26.77
25.46
1.31
0.54
0.15
0.62
0.19
0.44
0.47
20.09
0.53
20.62
16.53
4.08
0.42
0.12
3.55
0.89
2.66
2.66
13.16
0.73
13.89
10.57
3.32
0.53
0.14
2.65
0.66
1.99
1.89
Investor Presentation
29
Financial Snapshot
Total Income
EBITDA & EBITDA Margin
PAT & PAT Margin
EBITDA
EBITDA %
PAT
PAT %
77.61
71.89
55.58
15.8
11.36
11.14
8.64
7.99
4.44
9.18
6.60
5.19
4.02
1.88
1.05
FY21
FY22
FY23
FY21
FY22
FY23
FY21
FY22
FY23
Investor Presentation
30
All Figures In ₹ Cr
Financial Snapshot
ROE
15.27
(In %)
16.29
ROCE
17.36
(In %)
19.71
9.98
FY22
FY23
FY21
FY22
FY23
Debt to Equity
(In Times)
Interest Coverage
(In Times)
4.67
FY21
0.78
0.79
0.34
FY21
FY22
FY23
5.40
3.33
FY22
FY23
1.54
FY21
Investor Presentation
31
Profit & Loss Statement
Particular
Revenues
Other Income
Total Income
Raw Material Costs
Employee Costs
Other Expenses
Total Expenditure
EBITDA
Finance Costs
Depreciation
PBT
Tax
PAT
Total Comprehensive Income
FY23
69.66
2.23
71.89
54.68
2.08
3.77
60.53
11.36
2.01
0.50
8.85
2.24
6.60
6.64
FY22
75.82
1.79
77.61
63.50
2.10
3.37
68.97
8.64
2.46
0.46
5.73
1.70
4.02
4.04
In ₹ Cr
FY21
53.77
1.81
55.58
46.15
1.85
3.14
51.14
4.44
2.61
0.43
1.40
0.36
1.05
1.04
Investor Presentation
32
Balance Sheet
Equities & Liabilities
FY23
FY22
FY21
Assets
FY23
FY22
FY21
In ₹ Cr
Equity
Reserves
Net Worth
Non Current Liabilities
Long Term Borrowing
Lease Liabilities
Long Term Provision
Total Non Current Liabilities
Current Liabilities
Short Term Borrowings
Lease Liabilities
Trade Payables
Other Current Financial Liabilities
Income Tax Liabilities
Other Current Liabilities
Short Term Provision
Total Current Liabilities
Total Liabilities
Investor Presentation
10.55
29.99
10.55
15.81
10.55
11.87
40.53
26.35
22.42
5.23
0.88
0.19
6.30
8.44
0.19
3.11
0.04
0.19
3.33
17.66
0.01
4.03
0.23
0.19
4.44
13.54
0.05
18.00
28.38
40.54
0.34
1.95
3.13
0.02
32.07
78.90
0.56
1.27
4.02
0.03
51.94
81.62
0.40
0.38
4.34
0.02
59.26
86.13
Non Current Assets
Fixed Assets
Non Current Investments
Other Non Current Financial Assets
Deferred Tax Assets
Other Non Current Assets
2.65
0.43
2.28
0.14
0.72
1.67
0.43
2.22
0.16
0.71
Total Non Current Assets
6.23
5.20
1.26
0.43
2.12
0.15
0.87
4.83
Current Assets
Inventories
Trade Receivables
Cash & Bank Balance
Other Current Financial Assets
Other Current Assets
Total Current Assets
Total Assets
3.05
0.63
0.59
53.61
58.51
66.73
0.98
11.44
3.59
1.36
11.86
4.08
0.47
11.82
1.70
72.67
76.43
81.30
78.90
81.62
86.13
33
Cash Flow Statement
Particular
Cashflow from Operations
Cashflow from Investments
Cashflow from Financing
Net Cash flow
Opening Cash Balance
Closing Cash Balance
FY21
2.01
-0.11
-1.81
0.09
0.38
0.47
FY22
1.32
-0.85
0.42
0.89
0.47
1.36
In ₹ Cr
FY23
1.08
0.28
-1.73
-0.37
1.36
0.98
Investor Presentation
34
Stock Data
NSE: VAISHALI ISIN: INE972X01014
SHARE HOLDING PATTERN
As on 30-09-2023
Share Price (₹)
Market Capitalization (₹ Cr)
No. of Shares Outstanding
Face Value (₹)
52 week High-Low (₹)
200.00
150.00
100.00
50.00
0.00
Source - NSE
Investor Presentation
As on 24-11-2023
136.00
144.11
1,05,96,213
10
193.75 – 112.10
26.74%
Promoter & Promoter Group
Public
73.26%
Share Performance From 15 January 2020 Till Date
Volume
Price
138.80
35,00,000
30,00,000
25,00,000
20,00,000
15,00,000
10,00,000
5,00,000
0
35
The Way Ahead
Future Growth Drivers
Core Focus on Nutraceutical Products:
In the evolving landscape of healthcare and wellness, nutraceutical products have emerged as significant contributors to overall health. Acknowledging this shift, Vaishali Pharma is positioning itself to amplify its emphasis on these products. The Company’s objective is to capture emerging market patterns and carve a presence in this rapidly expanding sector. Furthermore, Vaishali Pharma has its sights set on expanding and diversifying its reach in this segment beyond the borders of India.
Geographic Expansion:
Diversifying Product Portfolio:
Boosting Production Capacity:
Vaishali Pharma is ambitiously extending its global footprint. By venturing into new markets and attracting clients from different countries, the company is making a noteworthy effort to enhance global health. This approach reflects commitment to not only growing market share but also contributing to the well-being of diverse communities worldwide.
Recognizing the vast opportunities that lie in product diversification, the company is channeling expertise and resources to broaden our product portfolio. This expansion not only showcases adaptability but also reinforces their commitment to cater to the diverse needs of our clientele, ensuring that company remain at the forefront of pharmaceutical innovation.
Vaishali Pharma intends to boost its production capacity, as they scale up their production, company will be better positioned to cater to the surging demand, ensuring timely and consistent product deliveries. Furthermore, such an expansion could firmly establish them as a dependable and credible player in the international marketplace, fostering trust among global partners and clients.
Investor Presentation
37
Vaishali Pharma Limited 706-709, Aravalli Business Center, R.C. Patel Road, Off Sodawala Lane, Borivali (West), Mumbai-400092. Phone: +91 22 42171819 (30Lines) Email: sales@vaishalipharma.com Website: www.vaishalipharma.com
Kirin Advisors Private Limited 713-B, Lodha Supremus II, Wagle Estate, Thane West – 400 604. Phone: 022 4100 2455 Email: info@kirinadvisors.com Website: www.kirinadvisors.com
Thank You